October 30, 2018CNS DrugsOpen Access

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

View Full Paper

Ask AI

Bookmark

Abstract

CBD was generally well tolerated. Most AEs were mild in severity; none were severe or serious. The safety and PK profile support twice-daily administration of CBD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Taylor et al. (2018) studied this question.

synapsesocial.com/papers/69d76f5faa68b335b4f316f5 https://doi.org/10.1007/s40263-018-0578-5

View Full Paper

Ask AI

Bookmark

Abstract

CBD was generally well tolerated. Most AEs were mild in severity; none were severe or serious. The safety and PK profile support twice-daily administration of CBD.

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

Abstract

Discussion

Cite This Study

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

Abstract

Discussion

Cite This Study

Also Consider

Also Consider